LAB eN2 Therapeutics Collaboration Grant
The LAB eN2 Therapeutics Collaboration Grant from Johns Hopkins University accelerates translational research for cardio-metabolic diseases and rare blood disorders, supporting IND-ready therapeutic development.
Funder: Johns Hopkins University
Due Dates: Rolling (Project Concept Forms)
Funding Amounts: Up to $4,000,000 per award; multi-stage projects to IND-ready candidates.
Summary: Accelerates translation of JHU faculty research into IND-ready therapies for cardio-metabolic diseases and rare blood disorders via industry collaboration.
Key Information: Only JHU faculty are eligible; initial submission requires a Project Concept Form.
Description
This internal funding program, a partnership between Johns Hopkins University, Novo Nordisk, and Evotec (LAB eN2), is designed to speed the translation of academic discoveries into IND-ready therapeutic candidates. The grant targets research advancing new biological targets, providing novel insights into disease mechanisms, and developing innovative tools for cardio-metabolic diseases (including diabetes and obesity) and rare blood disorders. The program encourages both technology platform and modality-agnostic proposals, with a strong emphasis on collaboration between academic and industry partners to bridge early-stage research and clinical application.
